

France's National Health Authority Warns Men Under 30 to Avoid Moderna Jab

By [Zero Hedge](#)

Global Research, November 11, 2021

[Zero Hedge](#) 10 November 2021

Region: [Europe](#)

Theme: [Science and Medicine](#)

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

To receive Global Research's Daily Newsletter (selected articles), [click here](#).

Visit and follow us on Instagram at [@crg_globalresearch](#).

The bad news for Moderna just keeps coming.

In the wake of a weak earnings report that [sent Moderna shares cratering](#) last week, French health authorities have just released a new advisory recommending that people under 30 don't get the Moderna vaccine, recommending that they choose the Pfizer-BioNTech jab instead.

The decision draws on recently released data showing that the risk of heart inflammation from Pfizer's jab "appears to be around five times lesser...compared to Moderna's spikevax jab", per an opinion published by [the HAS](#).

Cases of myocarditis mostly manifest within 7 days of vaccination, typically after the second dose has been given. Most patients who experience side effects are typically men under the age of 30, according to the HAS, which cited research studies.

HAS acts as an advisor to the French health sector but it doesn't have the power to ban medicines or vaccines. The recommendation will apply to first and second doses, as well as any "booster shot" doses available while the agency awaits additional data.

For French men and women aged 30 and over, however, HAS says it sees no problem with administering Moderna's Spikevax in this group, stating that its efficacy was slightly higher than Pfizer-BioNTech's jab.

Last month saw a handful of [Nordic nations place varying restrictions on Moderna's vaccine](#).

Tiny Iceland, meanwhile, has banned the Moderna jab from being used across the entire population.

Initially, Stockholm announced it would pause the use of Moderna for all of its population born in 1991 or after.

Helsinki followed suit, but halted the jabs for young, male Finns only based on a study involving Finland, Denmark, Norway, and Sweden which found that men under 30 had a slightly higher risk of developing heart inflammation. Oslo also suggested that young Norwegian men should consider choosing Comirnaty, the Pfizer jab, over Moderna's or any of the other options.

The EMA, the EU's medical watchdog, has acknowledged that inflammatory conditions like myocarditis and pericarditis, two different types of heart inflammation, should be added to a list of rare side effects from the vaccines that could be potentially harmful.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Featured image is from Zero Hedge

The original source of this article is [Zero Hedge](#)
Copyright © [Zero Hedge](#), [Zero Hedge](#), 2021

[Comment on Global Research Articles on our Facebook page](#)

[Become a Member of Global Research](#)

Articles by: [Zero Hedge](#)

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca
www.globalresearch.ca contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca